Literature DB >> 2959449

Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel.

D J Back1, S F Grimmer, N Shenoy, M L Orme.   

Abstract

The plasma concentrations of 3-keto-desogestrel have been measured by radioimmunoassay in a crossover study in nine healthy female volunteers given oral desogestrel (150 micrograms) and ethinyloestradiol (30 micrograms) and intravenous (i.v.) 3-keto-desogestrel (150 micrograms) and ethinyloestradiol (30 micrograms). Bioavailability ranged between 40.0 and 113% with a mean value ( +/- SD) of 76.1 +/- 22.5%. Only 3 subjects had a bioavailability of less than 70%. There was no significant difference in the elimination half life of 3-keto-desogestrel which was 12.6 +/- 4.1h following i.v. administration and 11.9 +/- 4.1h after oral administration of desogestrel.

Entities:  

Keywords:  Biology; Clinical Research; Contraception; Contraceptive Agents, Female; Contraceptive Agents, Progestin--pharmacodynamics; Contraceptive Agents--pharmacodynamics; Contraceptive Methods; Developed Countries; Economic Factors; Endocrine System; England; Europe; Family Planning; Hemic System; Hormones; Northern Europe; Oral Contraceptives; Physiology; Reproductive Control Agents; Research And Development; Research Methodology; Technology; United Kingdom

Mesh:

Substances:

Year:  1987        PMID: 2959449     DOI: 10.1016/s0010-7824(87)80021-5

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  10 in total

Review 1.  Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception.

Authors:  Frank Z Stanczyk
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

2.  The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel.

Authors:  Tuomas Korhonen; Ari Tolonen; Jouko Uusitalo; Stefan Lundgren; Jorma Jalonen; Kari Laine
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

Review 3.  Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects.

Authors:  Frank Z Stanczyk; Janet P Hapgood; Sharon Winer; Daniel R Mishell
Journal:  Endocr Rev       Date:  2012-12-13       Impact factor: 19.871

Review 4.  Clinical pharmacokinetics of contraceptive steroids. An update.

Authors:  G M Shenfield; J M Griffin
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

Review 5.  Comparative pharmacology of newer progestogens.

Authors:  H Kuhl
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

6.  Metabolism of the contraceptive steroid desogestrel by the intestinal mucosa.

Authors:  S Madden; D J Back; C A Martin; M L Orme
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

7.  Bioavailability and bioequivalence of etonogestrel from two oral formulations of desogestrel: Cerazette and Liseta.

Authors:  C J Timmer; N Srivastava; T O Dieben; A F Cohen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Oct-Dec       Impact factor: 2.569

8.  Randomized, Crossover and Single-Dose Bioquivalence Study of Two Oral Desogestrel Formulations (Film-Coated Tablets of 75 μg) in Healthy Female Volunteers.

Authors:  María Ángeles Pena; Emilio Sanz; Silvia Francisco; Ainhara Alonso; Zurine Abajo; Izaskun Felipe; Jaume Pascual; Digna Tost; Sandra Bailac
Journal:  Sci Pharm       Date:  2012-03-01

Review 9.  Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors:  Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal:  Pharmacol Ther       Date:  2020-12-13       Impact factor: 13.400

10.  Orexin Neurons Contribute to Central Modulation of Respiratory Drive by Progestins on ex vivo Newborn Rodent Preparations.

Authors:  Camille Loiseau; Alexis Casciato; Besma Barka; Florence Cayetanot; Laurence Bodineau
Journal:  Front Physiol       Date:  2019-09-27       Impact factor: 4.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.